Search
OS2966
go.drugbank.com/drugs/DB17207InvestigationalOS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]
PRGN-3006
go.drugbank.com/drugs/DB17229InvestigationalPRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface
Synonyms: Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surfaceST-36
go.drugbank.com/drugs/DB17275ExperimentalST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]
GVAX
go.drugbank.com/drugs/DB17276InvestigationalGVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine.
Dasiprotimut-T
go.drugbank.com/drugs/DB17287ExperimentalDasiprotimut-T is a personalized therapeutic vaccine against B-cell lymphomas.[A254701] It has been investigated in clinical trials.
LV305
go.drugbank.com/drugs/DB17288InvestigationalLV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with [G305].[L47346]
Leuvectin
go.drugbank.com/drugs/DB17303InvestigationalLeuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE
CAR BCMA-CS1
go.drugbank.com/drugs/DB17313ExperimentalCAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.
TPIV 200
go.drugbank.com/drugs/DB17318InvestigationalTPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).
ICG-136
go.drugbank.com/drugs/DB17343ExperimentalICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.